BRAF and cancer: Abnormal activation of kinases can contribute to cancer development and several kinases including B-RAF, MEK, BTK, KIT, ALK, BCR-ABL, EGFR, ERBB2 and VEGFR are clinically useful targets for cancer therapies2.